GlassScriptPhysician profile
Benjamin Merrill Perry
NPI 1710325758
$3,780.28
in general payments reported to CMS, 2019-2025
26 companies · $747 in 2025
The $747 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $67.09 · 2021: $476 · 2022: $343 · 2023: $1,033 · 2024: $829 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.72 |
| Education | $288.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $559.37 | 2019-2025 | |
| Janssen Biotech, INC. | $248.69 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $222.18 | 2019-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $221.25 | 2022-2025 | Sotyktu, Opdivo |
| Regeneron Healthcare Solutions, INC. | $218.65 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $197.52 | 2022-2025 | Adbry |
| Genzyme Corporation | $161.47 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $115.57 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $101.43 | 2019-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.44 | 2023-2024 | Spevigo |
| Amgen INC. | $91.74 | 2020-2023 | Otezla |
| Incyte Corporation | $84.92 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Biofrontera INC. | $65.13 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $52.06 | 2024-2025 | Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $52.00 | 2023-2024 | Vtama |
| Organon LLC | $51.19 | 2025 | Vtama |
| Ucb, INC. | $42.94 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $39.04 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $33.25 | 2019-2020 | |
| Pfizer INC. | $32.21 | 2021 | |
| Strata Skin Sciences, INC. | $29.41 | 2024 | Xtrac |
| Celgene Corporation | $21.98 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.78 | 2019 | |
| Genentech USA, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.